The Future Of Private Biotech Investment: A Q&A With Jonathan Leff
Long-time Warburg Pincus investor Jonathan Leff is making a move to Deerfield Management. He tells “The Pink Sheet” about his plans and contemplates what’s next for investment in private biotechs.
You may also be interested in...
Spectrum gains an approved drug with the deal and aims for label expansion. Talon’s high-profile investors are counting on an increase in Spectrum share price and post-acquisition milestones to break even.
Deerfield Management, the $3.5 billion health care hedge fund, is aggressively expanding its investments in private life sciences companies. As many VCs continue to struggle raising new funds Deerfield hopes its shift, combined with a flexible, research-driven approach to investing and a new involvement in the civic and academic activities shaping the sector, will secure its position as a top health care financier.
Rib-X will use the venture infusion to try to replicate Phase IIb data that indicated superiority to vancomycin for its broad-spectrum fluoroquinolone antibiotic.